What we are trying to do is to get new drugs that are patented into low- and middle-income countries as soon as possible – trying to…
In Conversation
We want to go from a business-to-business (B2B) model ... to a business-to-consumer (B2C) specialty pharma model by having our own sales organization in key European…
It must be remembered that patient empowerment is good for all of us, because all of us could be patients – or caregivers – one day.…
Over the years, we have developed a real expertise, predominantly in the cardiovascular field, but we will leverage this expertise to bring value to doctors and…
The new structure allows us to work more closely with our customers. The CDMO landscape has been transformed in the last 5-10 years; cooperation and partnerships…
Switzerland has a nimbus of innovation and is known for its love of precision
As a start-up company, we try to work in a very lean and dynamic way with a small team that leverages the expertise and support of…
During the pandemic, it became evident to hospital groups that having a partner that can offer a broad portfolio was a key advantage. We are currently…
There is a segment of people looking to take better care of their immune systems through healthy food, preventive measures, supplements, vitamins, and physical activity. Within…
The enthusiasm for our device comes from its simplicity paired with the many new functions. I often compare it to a smartphone which is very easy…
Our venture capital arm has a strategic focus which means that our main interest is not the mere financial return on investment but rather helping companies…
General attitudes towards the pharmaceutical industry have shifted, with an increasing realization of the importance of local research and production and an obligation in some geographies…
